ClinicalTrials.gg
RecruitingNCT01336790Updated Nov 22, 2023

International Lymphatic Disease and Lymphedema Registry

An observational study in Lymphedema, sponsored by Stanford University. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2023-11-22.

Sponsored by Stanford University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
5,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Lymphedema by Stanford University — 4 open to participants now, 4 under way, none of them phase 3. Lymphedema · Stanford University.

Started
2009
with 2 others
Observational
4 of 12
2 open now
Registered
3rd of 12
by date

Among the 12 studies in Lymphedema by Stanford University, this one is one of 3 that started in 2009, is one of 4 observational ones, and was the 3rd registered.

Lymphedema

529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.

Browse Lymphedema studies →

Open to participants now

4 of the 12 studies in Lymphedema by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lymphedema by Stanford University, or all of them as a file.
02

Study summary

The purpose of the International Lymphatic Disease and Lymphedema Patient Registry and Biorepository is to collect health information in order to study the disease classification, natural history, and impact of Lymphatic Disease, Lymphedema and Related Disorders and its treatments and medical outcomes.

Read the detailed description

This project represents the inauguration of an International Patient Registry for Lymphatic Diseases. This project will be completed through an affiliation with the Lymphatic Education \& Research Network, a non-profit organization whose mission is to promote research and the development of new therapies for patients with lymphatic diseases, including lymphedema. The registry will provide researchers with much-needed clinical data to study the impact of diseases of the lymphatic system, in order to develop improved treatments and find a cure for lymphatic diseases, lymphedema, and related disorders. The establishment of this initiative is a major step forward in research for direct study of groups of patients with lymphatic disease. In the future, this project will be able to be linked with a biorepository, in which tissue and blood samples derived from patients will be made available for research into human disease states. An international patient registry and tissue/cell bank program paves the way for future clinical trials of experimental drugs and therapies designed to treat lymphatic disease in human subjects.

03

Conditions studied

  • Lymphedema

Keywords

  • Lymphatic disease
  • Lymphedema
  • Lymphangiomatosis
  • Lymphangiectasia
  • Protein-losing enteropathy
  • Vascular Anomalies
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants (national and international participants) with the presence of lymphatic disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of lymphatic disease

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
5,000 participants (estimated)
06

What researchers measure

Primary outcomes

  1. prevalence of lymphatic disease

    Time frame: 15 years

Secondary outcomes

  1. socioeconomic impact of lymphatic disease

    The data in the registry will be utilized to determine the financial impact of requisite diagnostic and treatment interventions and will be analyzed to consider the relative contribution of third-party payer participation in the cost of care. The financial impact of disease and treatment will be addressed through the financial data entered by registry participants.

    Time frame: 15 years

07

Study locations

1 of 1 sites recruiting
  • Stanford University School of Medicine
    Stanford, California 94305, United States
    Recruiting
    • Principal Investigator · Contact
    • Stanley G Rockson · Principal investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Dec 2024 and a completion of Dec 2025. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2011
First posted
Apr 18, 2011
Start
Mar 2009
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2025
Last update
Nov 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01336790
Collaborators
Lymphatic Education & Research Network
Responsible party
Stanley Rockson (Allan and Tina Neill Professor of Lymphatic Research and Medicine, Stanford University) — Principal investigator
First posted
Apr 18, 2011
Start date
Mar 2009
Primary completion
Dec 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
Nov 22, 2023

Study contacts

Stanley Rockson, MD
Contact
(650) 7231396
Stanley G Rockson
principal investigator · Stanford University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion